Information on the #JohnsonAndJohnson clot shot

Information on the #JohnsonAndJohnson clot shot #Janssen https://physiciansforinformedconsent.org/wp-content/uploads/2021/05/Janssen-Johnson-Johnson-COVID-19-Vaccine-Risk-Statement.pdf Janssen-Johnson-Johnson-COVID-19-Vaccine-Risk-Statement Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personalContinue reading “Information on the #JohnsonAndJohnson clot shot”

JANSEN, ASTRAZENECA, PFIZER EUA DOCUMENTS

This “virus” the CDC is now being sued for because it can’t produce a single sample has a .02% mortality rate, less dangerous than the flu for almost everyone. Koch’s 4 Postulates have never been fulfilled. The PCR test is completely useless in determining the number of cases, according to its Nobel-Prize winning creator KariContinue reading “JANSEN, ASTRAZENECA, PFIZER EUA DOCUMENTS”

What Asbestos and Covid-19 Vaccines have in common?

Let that sink in… The Company that knew asbestos in their baby powder caused cancer for decades is now producing the COVID-19 vaccine. Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is aContinue reading “What Asbestos and Covid-19 Vaccines have in common?”

EMA and The Netherlands Biopharm Opportunities

The European Medicines Agency (EMA) is relocating from London to Amsterdam. According to EMA, the Seat Agreement allows EMA to function independently in the Netherlands. Similar agreements apply to other EU agencies located in the Netherlands. On Friday, 13 April 2018, the Dutch Council of Ministers agreed to sign the document. Quantify research reported earlier thisContinue reading “EMA and The Netherlands Biopharm Opportunities”

Daratumumab injection

Daratumumab injection The U.S. Food and Drug Administration granted accelerated approval to daratumumab injection (DARZALEX, Janssen Biotech, Inc.), administered as a single agent for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory toContinue reading “Daratumumab injection”